Brain zaps may curb meth cravings in small pilot trial

NCT ID NCT04449055

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This small pilot study tested whether a type of brain stimulation called transcranial magnetic stimulation (TMS) could help people with methamphetamine use disorder. Nineteen participants received daily TMS sessions for two weeks, then three times a week for two more weeks, while continuing their usual counseling. The study aimed to see if the approach was practical and if it could reduce cravings, improve mood, and change brain activity linked to addiction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

19 people

The number who actually took part.

Started

Oct 2020

Finished

Mar 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with an active methamphetamine use disorder * Is engaged in psychosocial treatment or articulates a plan to engage in psychosocial treatment for methamphetamine use disorder during the study period * Age 18 to 60 years * Able to consent for treatment and research participation * English-speaking * Receiving care from UIHC's Addiction Medicine service. This includes patients in the Crisis Stabilization Unit, seen by the inpatient consultation service, enrolling in partial hospitalization or intensive outpatient treatment, or seen in the outpatient Addiction Medicine clinics. Exclusion Criteria: * Age less than 18 years * Patients that are excluded during TMS assessment including: patients with epilepsy or seizure disorder, patients with implanted ferromagnetic equipment in their face or skull near the stimulation target. * Current medical treatment with clozapine or stimulants. * Current diagnosis of bipolar disorder, schizoaffective disorder, schizophrenia, that is deemed by research team psychiatrists not to have been drug-induced. Psychotic disorder not associated with drug use per the MINI International Neuropsychiatric Interview. Psychosis NOS, in remission, or drug-induced psychotic episodes are not exclusion criteria since these may be related to methamphetamine misuse. * Lacks the mental capacity to provide informed consent (i.e. not able to demonstrate understanding of the risks and benefits of participation) * Has a court appointed guardian. * Unstable medical illness. * Current diagnosis of neurological disorder or neurocognitive disorder. * Prior neurosurgical procedure. * History of seizure. * History of ECT treatment within the past three months. * History of any previous TMS treatment. * Known inability to complete the protocol, as assessed by asking them if they are able to make it to all visits for this study without assistance. MRI Exclusion criteria: * Implanted device including pacemaker, coronary stent, defibrillator, or neurostimulation device that is not MRI-compatible * Metal in body including bullets, shrapnel, metal slivers * Claustrophobia * Uncontrolled high blood pressure * Atrial fibrillation * Significant heart disease * Hemodynamic instability * Kidney disease * Pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Addiction, drug are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Iowa

    Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.